Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 01-2017 | 10-2016 | 09-2016 | 07-2016 | 06-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 33,498 | N/A | 35,208 | N/A | 36,819 |
| Receivables | 3,238 | N/A | N/A | N/A | N/A |
| TOTAL | $37,953 | $N/A | $35,813 | $N/A | $37,957 |
| Non-Current Assets | |||||
| PPE Net | 97 | N/A | N/A | N/A | N/A |
| Other Non-Current Assets | 0 | 0 | 50 | 0 | 50 |
| TOTAL | $97 | $N/A | $50 | $N/A | $50 |
| Total Assets | $38,050 | $N/A | $35,863 | $N/A | $38,007 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 755 | 0 | 431 | 0 | 187 |
| Accrued Expenses | 2,446 | N/A | 1,431 | N/A | 1,713 |
| TOTAL | $3,201 | $N/A | $1,891 | $N/A | $1,929 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 29 | N/A | 29 |
| TOTAL | $N/A | $N/A | $35 | $N/A | $42 |
| Total Liabilities | $3,201 | $N/A | $1,926 | $N/A | $1,971 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 9,713 | N/A | 1,881 | N/A | 1,880 |
| Common Shares | 10 | N/A | 27 | N/A | 27 |
| Retained earnings | -51,653 | N/A | -88,963 | N/A | -86,577 |
| Other shareholders' equity | -2,907 | 0 | 0 | 0 | 0 |
| TOTAL | $34,849 | $N/A | $33,937 | $N/A | $36,036 |
| Total Liabilities And Equity | $38,050 | $0 | $35,863 | $0 | $38,007 |